SCHEMBL5042252

SCHEMBL5042252

CCC(=O)Oc1ccc(CCC=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.53
ESR1 P03372 2/20 0.53
HIF1A Q16665 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RECQL P46063 1/20 0.53
THRB P10828 3/20 0.49
ELANE P08246 1/20 0.49
ACHE P22303 2/20 0.42
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
THRA P10827 1/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8387979 0.87 BCL9 (0.51) KMT2AESR1THRBLMNAHTT
SCHEMBL27864656 0.84 KMT2A (0.58) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL5427071 0.83 LMNA (0.50) KMT2AESR1SMN1; SMN2THRBELANE
SCHEMBL20593516 0.82 THRB (0.64) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL27942937 0.81 ACHE (0.52) ELANEACHE
SCHEMBL9332754 0.81 KMT2A (0.58) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL312147 0.80 KMT2A (0.76) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL1790460 0.79 THRB (0.59) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL1512672 0.78 KMT2A (0.63) KMT2AESR1HIF1ASMN1; SMN2RECQL
SCHEMBL27778741 0.78 KMT2A (0.54) KMT2AESR1HIF1ASMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351742-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC. (US) 2008-04-01 US disclosed
EP-1708992-B1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2007-08-08 EP disclosed
EP-1708992-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-10-11 EP disclosed
WO-2005080324-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-09-01 WO disclosed
US-20050171147-A1 Sulfonamide derivatives for the treatment of diseases PFIZER INC. 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171147-A1 Sulfonamide derivatives for the treatment of diseases SULT2A1, STS, SULT1A1 KMT2A 1600/4885ESR1 2341/4885HIF1A 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.